Rocket Pharmaceuticals, Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $2.59
- 52-Week Range
- $2.51 – $5.45
- Market Cap
- $281.02M
- P/E (TTM)
- —
- EPS (TTM)
- -0.17
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.76
- PEG Ratio
- —
- Return on Equity
- -4.77%
- Return on Assets
- -28.42%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 9.24
- Debt/Equity
- 0.07
- Total Debt
- $24.80M
- Free Cash Flow
- $86.14M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $22.07M
Market Snapshot
About
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing gene therapies for rare and devastating diseases. The company focuses on lentiviral vector-based gene therapies and gene editing approaches to treat genetic disorders including Fanconi Anemia, Danon disease, and Pyruvate Kinase Deficiency. Rocket Pharmaceuticals aims to deliver potentially curative treatments through a single administration that addresses the underlying genetic cause of these conditions.